Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
High dose naltrexone for dyskinesias induced by levodopa.
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Patient page. Multiple sclerosis and vitamin D.
Potassium-Retaining Diuretics: Amiloride
Investigating Axonal Damage in Multiple Sclerosis by Diffusion Tensor Spectroscopy.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
From "Wheelchair Circuit" to "Wheelchair Assessment Instrument for People with Multiple Sclerosis": Reliability and Validity Analysis of a Test to Assess Driving Skills in Manual Wheelchair Users With Multiple Sclerosis.
Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
A genome screen for multiple sclerosis in Italian families.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
The value of specialty pharmaceuticals - a systematic review.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

Pages